FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792683451> ?p ?o ?g. }

• W2792683451 endingPage "475" @default.
• W2792683451 startingPage "470" @default.
• W2792683451 abstract "Background Adenoviruses are double‐stranded DNA viruses that typically cause mild self‐limiting respiratory, ocular, and gastrointestinal infections. In immunocompromised patients, especially transplant recipients, the infection can be severe, with dissemination and multiorgan failure. In intestinal transplant recipients, the incidence is as high as 57%. To our knowledge, no standardized guidelines or U.S. Food and Drug Administration–approved medications exist for the treatment of adenovirus disease. Aims We describe two isolated intestinal transplant recipients who developed adenovirus disease (viremia with viral enteritis) that was managed with a new experimental drug, brincidofovir (an oral lipid conjugate prodrug of cidofovir), as salvage therapy. Results The first patient was a 44‐year‐old woman who developed adenoviral enteritis 1 month after transplantation, which resolved with ribavirin therapy. Two weeks later, the infection recurred, and brincidofovir was initiated. While receiving this therapy for 3 months, she developed severe acute rejection, which was managed with rabbit antithymocyte globulin followed by infliximab. Eventually, complete resolution of the rejection and adenoviral enteritis was achieved. At 12 months posttransplantation, the patient was healthy and tolerating enteral feeding. The second patient was a 28‐year‐old man who had undergone isolated intestinal transplantation 6 years before he presented with generalized weakness and an increased ostomy output; he was diagnosed with adenoviral enteritis. Maintenance immunosuppression was reduced, and brincidofovir was started. The infection resolved with a month of therapy. Six months after the infection, he was healthy and tolerating enteral feeding. Conclusion This is the first publication, to our knowledge, to describe two cases in which brincidofovir was used to successfully treat adenovirus infection in intestinal transplant recipients. Thus, these cases demonstrate that brincidofovir appears to be a safe and effective option in the management of adenoviral enteritis in these patients." @default.
• W2792683451 created "2018-03-29" @default.
• W2792683451 creator A5003953760 @default.
• W2792683451 creator A5025894621 @default.
• W2792683451 creator A5031266615 @default.
• W2792683451 creator A5036787987 @default.
• W2792683451 creator A5043900419 @default.
• W2792683451 creator A5064594588 @default.
• W2792683451 creator A5089616616 @default.
• W2792683451 date "2018-03-28" @default.
• W2792683451 modified "2023-09-27" @default.
• W2792683451 title "Brincidofovir as Salvage Therapy for Adenovirus Disease in Intestinal Transplant Recipients" @default.
• W2792683451 cites W1576873243 @default.
• W2792683451 cites W1829708015 @default.
• W2792683451 cites W1959270830 @default.
• W2792683451 cites W1965891265 @default.
• W2792683451 cites W1968444850 @default.
• W2792683451 cites W1982693802 @default.
• W2792683451 cites W1983506188 @default.
• W2792683451 cites W2005755543 @default.
• W2792683451 cites W2005826096 @default.
• W2792683451 cites W2021686939 @default.
• W2792683451 cites W2022636501 @default.
• W2792683451 cites W2035789688 @default.
• W2792683451 cites W2037302377 @default.
• W2792683451 cites W2041854719 @default.
• W2792683451 cites W2046950930 @default.
• W2792683451 cites W2051245686 @default.
• W2792683451 cites W2083686100 @default.
• W2792683451 cites W2137748387 @default.
• W2792683451 cites W2145639634 @default.
• W2792683451 cites W2158573664 @default.
• W2792683451 cites W2159604048 @default.
• W2792683451 cites W2238390992 @default.
• W2792683451 cites W2312658128 @default.
• W2792683451 cites W2313704944 @default.
• W2792683451 cites W2487775023 @default.
• W2792683451 cites W2570671915 @default.
• W2792683451 cites W2585488503 @default.
• W2792683451 cites W4249110784 @default.
• W2792683451 cites W90840010 @default.
• W2792683451 doi "https://doi.org/10.1002/phar.2094" @default.
• W2792683451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29457839" @default.
• W2792683451 hasPublicationYear "2018" @default.
• W2792683451 type Work @default.
• W2792683451 sameAs 2792683451 @default.
• W2792683451 citedByCount "12" @default.
• W2792683451 countsByYear W27926834512018 @default.
• W2792683451 countsByYear W27926834512019 @default.
• W2792683451 countsByYear W27926834512020 @default.
• W2792683451 countsByYear W27926834512021 @default.
• W2792683451 crossrefType "journal-article" @default.
• W2792683451 hasAuthorship W2792683451A5003953760 @default.
• W2792683451 hasAuthorship W2792683451A5025894621 @default.
• W2792683451 hasAuthorship W2792683451A5031266615 @default.
• W2792683451 hasAuthorship W2792683451A5036787987 @default.
• W2792683451 hasAuthorship W2792683451A5043900419 @default.
• W2792683451 hasAuthorship W2792683451A5064594588 @default.
• W2792683451 hasAuthorship W2792683451A5089616616 @default.
• W2792683451 hasConcept C126322002 @default.
• W2792683451 hasConcept C141071460 @default.
• W2792683451 hasConcept C203014093 @default.
• W2792683451 hasConcept C2522874641 @default.
• W2792683451 hasConcept C2776694085 @default.
• W2792683451 hasConcept C2776824251 @default.
• W2792683451 hasConcept C2780031333 @default.
• W2792683451 hasConcept C2780252810 @default.
• W2792683451 hasConcept C2780775027 @default.
• W2792683451 hasConcept C2781036101 @default.
• W2792683451 hasConcept C2911091166 @default.
• W2792683451 hasConcept C44315111 @default.
• W2792683451 hasConcept C71924100 @default.
• W2792683451 hasConcept C78722104 @default.
• W2792683451 hasConcept C90924648 @default.
• W2792683451 hasConceptScore W2792683451C126322002 @default.
• W2792683451 hasConceptScore W2792683451C141071460 @default.
• W2792683451 hasConceptScore W2792683451C203014093 @default.
• W2792683451 hasConceptScore W2792683451C2522874641 @default.
• W2792683451 hasConceptScore W2792683451C2776694085 @default.
• W2792683451 hasConceptScore W2792683451C2776824251 @default.
• W2792683451 hasConceptScore W2792683451C2780031333 @default.
• W2792683451 hasConceptScore W2792683451C2780252810 @default.
• W2792683451 hasConceptScore W2792683451C2780775027 @default.
• W2792683451 hasConceptScore W2792683451C2781036101 @default.
• W2792683451 hasConceptScore W2792683451C2911091166 @default.
• W2792683451 hasConceptScore W2792683451C44315111 @default.
• W2792683451 hasConceptScore W2792683451C71924100 @default.
• W2792683451 hasConceptScore W2792683451C78722104 @default.
• W2792683451 hasConceptScore W2792683451C90924648 @default.
• W2792683451 hasIssue "4" @default.
• W2792683451 hasLocation W27926834511 @default.
• W2792683451 hasLocation W27926834512 @default.
• W2792683451 hasOpenAccess W2792683451 @default.
• W2792683451 hasPrimaryLocation W27926834511 @default.
• W2792683451 hasRelatedWork W1608180050 @default.
• W2792683451 hasRelatedWork W1972965034 @default.
• W2792683451 hasRelatedWork W2004766863 @default.
• W2792683451 hasRelatedWork W2083886748 @default.

• next